Skip to main content

BioNxt Solutions Inc.

corporate_fare Company Profile

BioNxt Solutions Inc.

BNXTF·OTC·Life Sciences

BioNxt Solutions Inc. engages in the research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001 for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; BNT24005 for solid organic transplantation; and BNT24006, an oncology drug targeting chemotherapy platform and anticancer mTOR inhibitor. It also offers diagnostic and biosensor screening tests; transdermal patches and oral dissolvable formulations; and development of psychedelic medicine to treat mental health-related medical conditions, such as depression, anxiety, addiction, and trauma-related stress disorder. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

BioNxt Solutions Inc. (OTC:BNXTF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for BNXTF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10.

Recent high-impact activity:

  • BioNxt Seeks Up to $2.5M in Unit Placement Priced 34% Above Last Trade

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 3,000 shares in BNXTF as of the October 30, 2026 settlement, a 200.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)3,000 shares as of October 30, 2026
Change vs prior period▲ 200.0%
Days to cover1.00 at avg daily volume of 10,902

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.1737 +3.89% today
52-week range · as of 2026-11-17 $0.1001 – $0.80
Market cap
$23.64M
Volume
200 (0.0× avg)
3-mo avg 6.1K
Live data · 2026-11-22 11:12 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BNXTF - Latest Insights

BNXTF
Nov 16, 2026, 8:05 PM EST
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.1868
Real-time Price: $0.1737 info
Change: -$0.0131 (-7%) info
Market Cap: $23.639M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets